Biomay's Pipeline for Immunotherapy of Allergic Diseases

Biomay has assembled am impressive pipeline of innovative products for immunotherapy of allergic diseases based on its proprietary technology platforms.

The IgE immune apheresis device IgEnio®, co-developed with Fresenius Medical Care, has achieved CE mark designation and is currently introduced into European markets.

The most advanced peptide carrier fusion allergy vaccine BM32, indicated for grass pollen allergy, has completed phase IIb of clinical development and is ready for phase III pivotal trials.